Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma microRNA Signature as Predictive Marker of Clinical Response to Therapy During Multiple Sclerosis

11 Jun 2025

Abstract excerpt

OBJECTIVE: Despite the availability of effective therapies for Multiple Sclerosis (MS), the unpredictable nature of disease progression and the variability in individual treatment outcomes call for reliable biomarkers. This pilot study aims to investigate the potential of plasma circulating microRNAs (miRNAs) as predictive biomarkers for clinical responses to dimethyl fumarate (DMF), a widely used oral treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to MicroRNA in disease regulation
Share to Multiple Sclerosis Research Studies
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40501038
DOI: 10.1002/acn3.70093

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma microRNA Signature as Predictive Marker of Clinical Response to Therapy During Multiple SclerosisPMID 40501038Read ↗

miRNA Signature in CSF From Patients With Primary Progressive Multiple SclerosisSemantic proximity Read ↗

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.Semantic proximity Read ↗

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.Semantic proximity Read ↗

Circulating microRNAs as biomarkers in progressive multiple sclerosisSemantic proximity Read ↗

Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosisSemantic proximity Read ↗

Real-world Safety and Efficacy of Dimethyl Fumarate in Relapse-Remitting Multiple Sclerosis Patients: A Regional Cohort Report of the Iranian PatientsSemantic proximity Read ↗

Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosisSemantic proximity Read ↗

MicroRNAs in blood and cerebrospinal fluid as diagnostic biomarkers of multiple sclerosis and to monitor disease progressionSemantic proximity Read ↗

Profiling of small non-coding RNAs across cellular and biofluid compartments: implications for multiple sclerosis immunopathologySemantic proximity Read ↗

The role of miRNAs in multiple sclerosis pathogenesis, diagnosis, and therapeutic resistanceSemantic proximity Read ↗

Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosisSemantic proximity Read ↗

Identification of MS-specific serum miRNAs in an international multicenter studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.